Eledon Pharmaceuticals, Inc.
ELDN
$3.58
-$0.01-0.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -500.85% | 76.59% | -122.68% | 75.02% | 72.51% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 366.09% | -130.99% | 101.77% | -129.30% | -153.42% |
| Change in Net Operating Assets | -149.52% | 407.05% | -81.03% | 9.40% | -761.51% |
| Cash from Operations | -40.80% | 25.79% | -23.01% | -127.85% | -83.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 53.03% | 56.81% | 196.90% | 175.12% | -60.22% |
| Cash from Investing | 53.03% | 56.81% | 196.90% | 175.12% | -60.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -33.02% | -100.00% | -100.00% | 11,400.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -33.02% | -100.00% | -100.00% | 11,400.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -38.19% | 38.71% | 89.26% | -113.52% | -1,255.61% |